46,193 Shares in Kenvue Inc. $KVUE Acquired by K2 Principal Fund L.P.

K2 Principal Fund L.P. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, Holdings Channel.com reports. The fund bought 46,193 shares of the company’s stock, valued at approximately $797,000.

A number of other large investors have also recently made changes to their positions in the company. Physician Wealth Advisors Inc. increased its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. B & T Capital Management DBA Alpha Capital Management increased its stake in shares of Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after buying an additional 712 shares during the period. Philip James Wealth Mangement LLC increased its stake in shares of Kenvue by 5.5% during the fourth quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock worth $240,000 after buying an additional 726 shares during the period. IFG Advisory LLC increased its stake in shares of Kenvue by 5.4% during the fourth quarter. IFG Advisory LLC now owns 15,051 shares of the company’s stock worth $260,000 after buying an additional 766 shares during the period. Finally, Phoenix Financial Ltd. increased its stake in Kenvue by 5.4% in the fourth quarter. Phoenix Financial Ltd. now owns 15,195 shares of the company’s stock valued at $262,000 after purchasing an additional 783 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $18.13 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The stock has a fifty day moving average price of $17.43 and a 200 day moving average price of $17.53. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The company has a market cap of $34.80 billion, a PE ratio of 21.32, a P/E/G ratio of 1.38 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same period last year, the company earned $0.24 earnings per share. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Buying and Selling at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.59% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Barclays dropped their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Finally, Citigroup dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.